| Project/Area Number |
24792004
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pathobiological dentistry/Dental radiology
|
|---|
| Research Institution | University of the Ryukyus |
|---|
Principal Investigator |
KINA Shinichiro 琉球大学, 医学(系)研究科(研究院), 助教 (40422422)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
|
|---|
| Keywords | 抗癌剤耐性 / PDGF 受容体 / 抗癌剤 / 分子標的薬 / Met / 舌癌 / 癌治療 |
|---|
| Outline of Final Research Achievements |
For decades, platinum drugs have been the mainstay of cancer treatment. However, over time, drug resistance develops, leaving few treatment options. Here we show that platelet-derived growth factor receptor (PDGF αreceptor) plays a key role in chemotherapy resistance by upregulating HGF（Hepatocyte Growth Factor) receptor protein(Met). Chemotherapy induced Met protein expression in cancer cells. Chemotherapy-induced Met protein upregulation is inhibited by PDGF receptor inhibitor Imatinib. Chemotherapy induced PDGF receptor tyrosine phosphorylation. PDGF receptor inhibition significantly increased chemotherapy-induced cancer death. PDGF receptor inhibitors are widely used in clinical settings, suggesting that the clinical translation of our findings could reduce the suffering of people from drug resistance.
|
